TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury. In preclinical studies, TT-301 has been shown to act by inhibiting the overproduction of inflammatory cytokines, such as interleukin-1 (IL-1Beta), tumour necrosis factor-alpha (TNF-Alpha), a key disease process associated with many inflammatory and degenerative diseases. TT-301 was designed to cross the blood-brain-barrier and has the flexibility to be administered by injection or orally. In preclinical studies to date, TT-301 has shown a favorable safety profile and a significant therapeutic benefit in animal models of disease. TT-301 has been used in trials studying the treatment of traumatic brain injury.